Development and validation an HPLC-UV method for determination of esomeprazole and pirfenidone simultaneously in rat plasma: Application to a drug monitoring study
| dc.authorid | 0000-0001-5036-0475 | |
| dc.contributor.author | Dural, Emrah | |
| dc.contributor.author | Köz, Sema Tülay | |
| dc.contributor.author | Köz, Süleyman | |
| dc.date.accessioned | 2021-06-10T08:45:34Z | |
| dc.date.available | 2021-06-10T08:45:34Z | |
| dc.date.issued | 2021 | |
| dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | |
| dc.description.abstract | Background and Aims: It has been observed that the combined treatment of esomeprazole and pirfenidone provides increased efficacy in the treatment of pulmonary fibrosis disease, recently. The aim of this study is to develop a simple, sensitive, and reliable high-performance liquid chromatography method to be used in drug monitoring to increase the effectiveness of esomeprazole and pirfenidone in treatment and to reduce their adverse effects. Methods: Separation was conducted with a C18 reverse-phase column (4.6 mm x 250 mm, 5 mu m) used as a mobile phase prepared with the phosphate buffer (10 mM KH2PO4 and 10 mM K2HPO4) and acetonitrile (60:40, v/v) by an isocratic flow (1 mL/min). Mobile phase pH was adjusted to 3.0. Ultraviolet detection was accomplished at 305 nm. The column oven was held at 35 degrees C to ensure an efficient analytical separation. Results: Analytical recovery of esomeprazole was between 92.43 and 105.36% and for pirfenidone it was found between 89.56 and 104.32%. Accuracy values of esomeprazole and pirfenidone were determined between (-2.90) - 4.22 and (-4.45) - 5.78, respectively. Precision (RSD%) was <= 7.89. The quantification limit was determined as 0.58 and 0.36 ng/mL. Plasma esomeprazole and pirfenidone levels were found as 0.87-8296.87 ng/mL (612.99 +/- 2212.20, mean +/- standard deviation) and 0.45-238.60 ng/mL (61.44 +/- 76.35, mean +/- standard deviation), respectively. Conclusion: Unexpectedly high RSD values were observed in both plasma (360.88%) and dose-rated results (89.61%) of esomeprazole, and pirfenidone were thought to be related to individual metabolism differences. | |
| dc.description.sponsorship | Cumhuriyet University | en_US |
| dc.identifier.citation | Dural, E., Köz, S. T. ve Köz, S. (2021). Development and validation an HPLC-UV method for determination of esomeprazole and pirfenidone simultaneously in rat plasma: Application to a drug monitoring study. Istanbul Journal of Pharmacy, 51(1), 16-25. https://dx.doi.org/10.26650/IstanbulJPharm.2020.0091 | |
| dc.identifier.doi | 10.26650/IstanbulJPharm.2020.0091 | |
| dc.identifier.endpage | 25 | |
| dc.identifier.issn | 2587-2087 | |
| dc.identifier.issue | 1 | |
| dc.identifier.startpage | 16 | |
| dc.identifier.uri | https://dx.doi.org/10.26650/IstanbulJPharm.2020.0091 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12511/7124 | |
| dc.identifier.volume | 51 | |
| dc.identifier.wosquality | N/A | |
| dc.indekslendigikaynak | Web of Science | |
| dc.language.iso | en | |
| dc.publisher | Istanbul University | |
| dc.relation.ispartof | Istanbul Journal of Pharmacy | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | Attribution-NonCommercial 4.0 International | * |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | * |
| dc.subject | Esomeprazole | |
| dc.subject | Pirfenidone | |
| dc.subject | Rat Plasma | |
| dc.subject | Method Validation | |
| dc.subject | HPLC-UV | |
| dc.title | Development and validation an HPLC-UV method for determination of esomeprazole and pirfenidone simultaneously in rat plasma: Application to a drug monitoring study | |
| dc.type | Article |
